Biotheranostics announces Lee Newcomer, M.D. to join its Board of Directors

Biotheranostics, Inc., today announced that Lee Newcomer, M.D., has been elected to its Board of Directors. Dr. Newcomer brings more than 30 years of healthcare experience including serving as the Chief Medical Officer of UnitedHealthcare and Senior
Vice President Oncology and Genetics at UnitedHealthcare. He was a founding executive of Vivius, a consumer directed venture that allowed consumers to create their own personalized health plans and a former chairman of Park Nicollet Health Systems. He practiced medical oncology for nine years before joining the healthcare industry. Throughout his career, he has focused on making cancer care more effective and affordable. His expertise in medical oncology, medical care delivery, health plan strategy and management, payment systems and business development will contribute to Biotheranostics’ growth.

“We are pleased that Lee has accepted our invitation to join the Biotheranostics Board,” said Don Hardison, President and Chief Executive Officer. “His extensive experience in cancer care management and commercial health plans will be invaluable as we continue to rapidly grow our business and evolve our proprietary tests to address key unmet needs of the hundreds of thousands
of patients diagnosed annually with early-stage breast cancer and metastatic cancer.

Newcomer added, “I am excited to work with Biotheranostics as the company continues its important mission developing and providing accurate, actionable, molecular-based information for oncologists in order to better define the best individual treatment for cancer patients.”

About Biotheranostics
Biotheranostics, Inc. operates a CLIA-certified and CAP-accredited diagnostic laboratory in San Diego, California. Biotheranostics, Inc., is a leading healthcare provider in the oncology field assisting physicians in the treatment of cancer patients. Its suite of proprietary molecular diagnostic tests provides important information to physicians to tailor treatment to individual patients. The company's Breast Cancer Index® and CancerTYPE ID® tests address a variety of unmet medical needs in the management of cancer patients, and extensive clinical studies have confirmed the accuracy, clinical validity, clinical utility, and cost-effectiveness of the tests. Learn more at www.biotheranostics.com.

Biotheranostics, Inc.

Biotheranostics, Inc.
Cancer diagnostics

Downloads

DownloadPress Release

Latest News

Valneva reports successful outcome of Phase 2 run-in for its Lyme disease vaccine candidate

Valneva SE has announced progress of its ongoing Phase 2 study for its leading, unique Lyme disease vaccine candidate, VLA15, into the main study phase

New data further validates Breast Cancer Index ability to predict extended endocrine therapy benefit

Biotheranostics, Inc. announces new pivotal data on the Breast Cancer Index that further validates its ability to accurately predict which women with early-stage, hormone receptor positive breast cancer will benefit from extended endocrine therapy

Valneva reports further positive results for its Chikungunya Vaccine Candidate

Phase I unblinded results up to month 7 showed an excellent immunogenicity and safety profile confirming Valneva's unique, single-shot vaccine candidate

Biotheranostics announces Lee Newcomer, M.D. to join its Board of Directors

Biotheranostics, Inc., has announced that Lee Newcomer, M.D., has been elected to its Board of Directors. Dr. Newcomer brings more than 30 years of healthcare experience including serving as the Chief Medical Officer of UnitedHealthcare and Senior Vice President Oncology and Genetics at UnitedHealthcare

Zipline selected as 2019 Red Herring Top 100 North America Winner

ZipLine Medical, Inc. was selected as a winner of the Red Herring Top 100 North America award, which recognizes the continent's most exciting and innovative private technology companies

MVM announces partial sale of its holding in Ambio

MVM Partners announces the partial sale of its holding in Ambio to The Carlyle Group